Preventing SARS-CoV-2 infection by blocking a tissue serine protease

Currently, there are no proven pharmacologic interventions to reduce the clinical impact and prevent complications of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, the cause of the ongoing Coronavirus Disease of 2019 (COVID-19) pandemic. Selecting specific pharmacologic...

Descripción completa

Detalles Bibliográficos
Autores principales: Jankousky, Katherine C., Schultz, Jonathan, Windham, Samuel, Henao-Martínez, Andrés F., Franco-Paredes, Carlos, Shapiro, Leland
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288835/
https://www.ncbi.nlm.nih.gov/pubmed/32577236
http://dx.doi.org/10.1177/2049936120933076
Descripción
Sumario:Currently, there are no proven pharmacologic interventions to reduce the clinical impact and prevent complications of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, the cause of the ongoing Coronavirus Disease of 2019 (COVID-19) pandemic. Selecting specific pharmacological targets for the treatment of viral pathogens has traditionally relied in blockage of specific steps in their replicative lifecycle in human cells. However, an alternative approach is reducing the molecular cleavage of the viral surface spike protein of SARS-CoV-2 to prevent viral entry into epithelial cells.

Ejemplares similares